Evidence map›Paper›PMID 41560678›Full record

ReviewMycoses2026

Emerging Frontiers in Clinical Mycology: Innovations, Insights, and Impacts.

A Apostolopoulou, A G Stewart, H Yoon, J M Steinbrink, D Z P Friedman, L Ostrosky-Zeichner, I S Schwartz, Mycoses Study Group Education and Research Consortium (MSGERC)

Abstract readReview
In one paragraph

Review in Mycoses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

A ApostolopoulouDivision of Infectious Diseases, Department of Medicine, New York Presbyterian/Weill Cornell Medical Center, New York, New York, USA.ORCID https://orcid.org/0000-0002-8874-0980
A G StewartTransplant and Immunocompromised Host Infectious Diseases, Infectious Diseases Division, Massachusetts General Hospital, Boston, Massachusetts, USA.
H YoonDivision of Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, New York, USA.
J M SteinbrinkDivision of Infectious Diseases, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.
D Z P FriedmanSection of Infectious Diseases and Public Health, Department of Medicine, University of Chicago, Chicago, Illinois, USA.ORCID https://orcid.org/0000-0002-3442-7454
L Ostrosky-ZeichnerDivision of Infectious Diseases, McGovern Medical School at UTHealth, Houston, Texas, USA.
I S SchwartzDivision of Infectious Diseases, Department of Medicine, Duke University School of Medicine, Durham, North Carolina, USA.ORCID https://orcid.org/0000-0002-7522-0281
Mycoses Study Group Education and Research Consortium (MSGERC)

Funding

Convalescent Plasma to Limit Coronavirus Associated ComplicationsUL1TR003167 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI KARP, DANIEL D, MCPHERSON, DAVID D · 2019 to 2023
$45.3M
Antibody Biomarkers of Cryptococcosis in Immunosuppressed Solid Organ Transplant RecipientsK23AI177939 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI Hyun Ah Yoon · 2024 to 2026
$599k
Novel Host-Response Biomarker Diagnostics for Invasive AspergillosisK23AI187748 · NIAID · DUKE UNIVERSITY · PI Julie Marie Steinbrink · 2025 to 2026
$363k
Irma L. and Abram S. Croll Charitable TrustNCATS NIH HHS UL1 TR003167NIAID NIH HHS K23 AI177939NIAID NIH HHS K23 AI187748NIH HHS K23-AI177939NIH HHS K23-AI187748NIH HHS UL1TR003167
6 · The paper itself

Abstract

The Mycoses Study Group Education and Research Consortium (MSGERC)-a group comprising clinicians, researchers, patients, and industry partners-meets every 2 years to review the most significant challenges facing the clinical mycology community and plan research, education, and advocacy strategies to prevent fungal infections and improve outcomes. Key themes of the 2024 biennial meeting included emergence of antifungal resistance, the effects of climate change on incidence of IFI, recent healthcare-and community-associated outbreaks and their management, and the potential benefits of novel approaches, such as innovative study designs, host-directed diagnostics and therapies, and artificial intelligence in clinical and academic mycology.

Indexed as

MycologyMycosesAntifungal AgentsArtificial IntelligenceClimate ChangeDisease OutbreaksDrug Resistance, FungalHumansAntifungal Agentsartificial intelligenceclimate changediagnosticsfungal infectionmycoses

Identifiers

PMID41560678
PMCPMC12820753

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.